Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Henan Hualong Biotechnology Co., Ltd., established on 2012-05-07, Business scope includes biotechnology development,consult,Serve;Stem Cell Storage Services(Except where prohibited by the state).(All projects involving licensed operation shall be operated with a license)

Chengnuo Regenerative Medicine Technology (Zhuhai Hengqin New Area) Co., Ltd., established on 2020-12-17, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Hangzhou Xiangyu Medical Laboratory Co., Ltd., established on 2016-08-04, Business scope includes technology development,technical consulting:Medical Testing Technology;Serve:Medical Laboratory,Clinical Cytomolecular Genetics Major,clinical immunization,Serology major(The operating permit);Sales:Class III medical devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Zhongbang Stem Cell Technology Co., Ltd., established on 2017-11-23, Business scope includes stem cells,Immune Cells,Fibroblast technology development,Research and development of stem cell detection technology,technical consulting,Technology Exchange,technology transfer,Technology research and development of gene therapy technology and gene medicine,Diagnostic reagent research and development;Import and export services of various commodities and technologies(Except where restricted or prohibited by the country);Organize cultural and artistic exchange activities,Conference Services,Health Consulting Services(no medical);Class II medical device,cosmetic,Sales of daily necessities;medical service;hospital management**(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Consiglio Nazionale delle Ricerche is the largest public research facility in Italy. Founded in 1923, it has worked in the past as a government consultant on research and as a funding fund for university research grants. Since 1989 the CNR is a research institution, with the mission of carrying out research projects, promoting innovation and competitiveness of the national industrial system, the internationalization of the national research system, and providing technologies and solutions to emerging needs in the public and private sectors. . Objectives that are achieved through a wealth of human resources that has over 8000 employees, half of which is represented by researchers and technologists. About 4,000 young researchers are involved in post-doctoral research activities in the laboratories of the Institute, while an important contribution comes from collaborations, including international ones, with researchers from universities and companies, thus strengthening the national research system.

Canvax Biotech is a biotech company that manufactures and supplies innovative solutions, services, kits and R&D Reagents. Since its foundation in 2001, Canvax offers reliable, cost-effective and easy-to-use innovative tools for research. Based in Córdoba (Spain), since its beginning it has focused on R&D of multiplex high throughput platforms (HTS) for Drug discovery and Diagnostic applied biosensors. Over a decade later, Canvax is a worldwide leading expert in GPCR expression in heterologous cells, with important patents and exclusive know-how. Canvax prides itself to be the first company to get an unprecedented milestone that could revolutionize the Diagnostics sector: Canvax established stable high-level expression of odour GPCRs into heterologous cell lines in 2014. This key milestone, that could be applied in diagnostic, perfume and cosmetic industry, are being employed to obtain a molecular nose, a sensitive and non-invasive diagnostic molecular device for early detection of cancer, as the nose of trained dogs do. Thanks to this project, Canvax was awarded, in 2013, with the largest Public & Private Contract for Pre competitive Technology Development in Spanish history.

Bernhard Nocht Institute for Tropical Medicine; (Bernhard-Nocht-Institut für Tropenmedizin) (BNITM) in Hamburg is Germany's largest institution for tropical medicine in Germany with a workforce of about 250 people in Hamburg. It is member of the Leibniz-Association.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany.

Guangdong Zhaotai Cell Biotechnology Co., Ltd., established on 2020-11-27, Business scope includes general items:Medical Research and Experimental Development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Jiangsu Lu's Biotechnology Co., Ltd., established on 2021-06-22, Business scope includes licensed projects:pharmaceutical production;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Production of Class I Medical Devices;electronics sales;Instrument sales;Machinery sales;Sales of office equipment consumables;Medical equipment rental;Engineering and Technology Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.